ALKS250117C36000
- 0.00
- 0.000.00%
Alkermes Newsroom
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating, Announces Target Price $40
Analysts Conflicted on These Healthcare Names: Talkspace (TALK), Centene (CNC) and Alkermes (ALKS)
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), DocGo (DCGO) and Alkermes (ALKS)
Piper Sandler Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $37
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating
BofA Securities Maintains Alkermes(ALKS.US) With Hold Rating
Bank of America Securities Keeps Their Hold Rating on Alkermes (ALKS)
Mizuho Securities Maintains Alkermes(ALKS.US) With Buy Rating, Announces Target Price $40
Alkermes Is Maintained at Outperform by Mizuho
Alkermes Analyst Ratings
TD Cowen Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $35
Stifel Maintains Alkermes(ALKS.US) With Buy Rating, Maintains Target Price $36
Alkermes Analyst Ratings
Stifel Upgrades Alkermes(ALKS.US) to Buy Rating, Raises Target Price to $36
Alkermes Inc.: Strong Q3 Performance and Strategic Growth Drive Buy Rating
Alkermes (ALKS) Gets a Hold From J.P. Morgan
Alkermes Is Maintained at Neutral by JP Morgan
Alkermes: Balancing Near-Term Challenges With Long-Term Orexin Market Potential Justifies Hold Rating
Cantor Fitzgerald Maintains Alkermes(ALKS.US) With Buy Rating, Cuts Target Price to $43
H.C. Wainwright Maintains Alkermes(ALKS.US) With Hold Rating, Maintains Target Price $37